Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Estradiol 6 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1475-2015Class IITerminatedSep 23, 2015Estradiol 50 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1474-2015Class IITerminatedSep 23, 2015Estradiol 4 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1473-2015Class IITerminatedSep 23, 2015Estradiol 3 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1472-2015Class IITerminatedSep 23, 2015Estradiol 25 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1471-2015Class IITerminatedSep 23, 2015Estradiol 22 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1470-2015Class IITerminatedSep 23, 2015Estradiol 20 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1469-2015Class IITerminatedSep 23, 2015Estradiol 18 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1468-2015Class IITerminatedSep 23, 2015Estradiol 15 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1467-2015Class IITerminatedSep 23, 2015Estradiol 12.5 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1466-2015Class IITerminatedSep 23, 2015Estradiol 100 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1465-2015Class IITerminatedSep 23, 2015Estradiol 10 mg Sterile PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1464-2015Class IITerminatedSep 23, 2015DMPS (Sodium 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1463-2015Class IITerminatedSep 23, 2015Dexpanthenol 250 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1462-2015Class IITerminatedSep 23, 2015Dexpanthenol 215 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1461-2015Class IITerminatedSep 23, 2015Cyanocobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1460-2015Class IITerminatedSep 23, 2015Cyanocobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1459-2015Class IITerminatedSep 23, 2015Cyanocobalamin 10 mg PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1458-2015Class IITerminatedSep 23, 2015Cyanocobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1457-2015Class IITerminatedSep 23, 2015Copper (Cupric)Sulfate 2 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1456-2015Class IITerminatedSep 23, 2015Collagenase 250 units/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1455-2015Class IITerminatedSep 23, 2015Clotrimazole 2% Otic SuspensionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1454-2015Class IITerminatedSep 23, 2015Cholecalciferol 600Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1453-2015Class IITerminatedSep 23, 2015Cholecalciferol 500Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1452-2015Class IITerminatedSep 23, 2015Cholecalciferol 100Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1451-2015Class IITerminatedSep 23, 2015Cholecalciferol 50Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1450-2015Class IITerminatedSep 23, 2015Bupivacaine 15 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1449-2015Class IITerminatedSep 23, 2015Bupivacaine 40 mg/ml +Baclofen 130 mcg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1448-2015Class IITerminatedSep 23, 2015Brompheniramine Maleate 20 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1447-2015Class IITerminatedSep 23, 2015Biotin10 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1446-2015Class IITerminatedSep 23, 2015Baclofen 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1445-2015Class IITerminatedSep 23, 2015B-Complex InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1444-2015Class IITerminatedSep 23, 2015Ascorbic Acid 1.25% Glutathione 1.25% DMSO 6.25% Ophthalmic SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1443-2015Class IITerminatedSep 23, 2015Ascorbic Acid 500 mg/ml Injectable VialLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1442-2015Class IITerminatedSep 23, 2015L-Arginine 100 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1441-2015Class IITerminatedSep 23, 2015Alprostadil 50 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1440-2015Class IITerminatedSep 23, 2015Alprostadil 40 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1439-2015Class IITerminatedSep 23, 2015Alprostadil 20 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1438-2015Class IITerminatedSep 23, 2015Alprostadil 100 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1437-2015Class IITerminatedSep 23, 2015Alprostadil 10 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1436-2015